Most upside (3 months)

The Most Upside chart above shows the companies potential share price gain (%) (the potential share price increase from the current share to the broker target price)

  Company % change  
  Dunelm Group PLC 68.13  
  Galliford Try PLC 55.65  
  Glencore PLC 48.72  
  FlyBe 46.67  
  Anglo American PLC 42.52  
  Tesco PLC 39.19  
  BT Group PLC 35.39  
  Rio Tinto PLC 25.42  
  Morgan Advanced Materials 24.71  
  Royal Dutch Shell 24.62  
  BHP Billiton PLC 24.48  
  BP PLC 24.33  
  Booker Group PLC 23.33  
  Pets At Home Group Plc 22.85  
  Barclays PLC 22.84  

Performance Analysis (6 Months)

The performance analysis chart above provides a detailed breakdown of Buy, Sell and Hold recommendations for the selected bank or stockbroker. To see a full explanation of how to use this chart, please visit the performance analysis explanation page.

Recommendation Summary (3 months)


  • Broker views: Pharma and mining

    19 May 2017 | Shire
    Equity analysts at HSBC have downgraded their investment rating on Shire Pharmaceuticals (LON:SHP) to 'reduce' (from 'hold'), despite the company reporting positive data from the HELP study...
  • Broker views: TalkTalk and Domino's

    21 April 2017 | Domino's Pizza Group
    Equity research analysts at HSBC have upgraded their recommendation on telecom group TalkTalk (LON:TALK) to buy from hold after reviewing Ofcom's WLA fibre price controls. "The WLA review proposes...
  • Broker views: Oil & gas, broadcasting and building materials

    07 April 2017 | Amec Foster Wheeler
    Numis has been assessing whether Wood Group's (LON:WG.) acquisition of Amec Foster Wheeler (LON:AMFW), assuming it completes successfully, makes sense for its shareholders and concluded that the...
  • Broker views: G4S and Circassia

    20 March 2017 | G4S
    Equity research analysts at HSBC have downgraded their investment rating on G4S (LON:GFS) to reduce (from hold) saying it's a "tricky stock" and that it is not entirely sure what will emerge from...
  • Broker views: Pharmaceuticals

    17 March 2017 | Hikma Pharmaceuticals
    HSBC has downgraded its recommendation on Hikma Pharma (LON:HIK) to reduce (from hold) saying that it remains concerned on the outlook for generic drug pricing. The bank explained: "We are...

HSBC Notes